Tag Archives: Sanofi

Dupixent® Receives Landmark Approval in Japan for Chronic Spontaneous Urticaria Treatment

(IN BRIEF) Japan’s Ministry of Health, Labor and Welfare (MHLW) has authorized the marketing and manufacturing of Dupixent® (dupilumab) for treating chronic spontaneous urticaria (CSU) in patients aged 12 years and older. This approval marks a significant milestone as Japan … Read the full press release

Sanofi’s Dupixent Receives FDA Approval for Pediatric Eosinophilic Esophagitis (EoE) Treatment

(IN BRIEF) The U.S. Food and Drug Administration (FDA) has granted approval for Dupixent® (dupilumab) to treat pediatric patients aged 1 to 11 years, weighing at least 15 kg, who suffer from eosinophilic esophagitis (EoE). Dupixent is now the first … Read the full press release

Sanofi Ceases Development of Tusamitamab Ravtansine for NSCLC after Trial Misses Primary Endpoint

(IN BRIEF) Sanofi has announced the discontinuation of the global clinical development program for tusamitamab ravtansine, following an interim analysis of the Phase 3 CARMEN-LC03 trial. The trial assessed tusamitamab ravtansine as a monotherapy in previously treated metastatic non-squamous non-small … Read the full press release

Sarclisa Combination Therapy Boosts Myeloma Remission Rates in Phase 3 Trial

(IN BRIEF) In the Phase 3 IsKia trial presented at the American Society of Hematology (ASH) Annual Meeting, Sarclisa® (isatuximab) combined with carfilzomib, lenalidomide, and dexamethasone (KRd) demonstrated a significant improvement in achieving minimal residual disease (MRD) negativity among newly … Read the full press release

Sanofi’s Robust Pipeline and Strategic Focus Aim to Lead Immunology Industry

(IN BRIEF) Sanofi is showcasing its ambitious pipeline transformation strategy, which includes a record 12 potential blockbuster opportunities currently under clinical evaluation. Among these, there are nine innovative medicines and vaccines with peak sales potential ranging from €2 to €5 … Read the full press release

Sarclisa Combination Treatment Shows Promise in Phase 3 Trial for Newly Diagnosed Multiple Myeloma Patients

(IN BRIEF) The Phase 3 IMROZ trial, assessing the use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd), has achieved its primary efficacy endpoint at a planned interim analysis. The trial demonstrated a statistically significant improvement … Read the full press release

Sanofi’s CHC Launches Shared Care Collective with Global Experts to Advance Health and Sustainability Initiatives

(IN BRIEF) Sanofi’s Consumer Healthcare business unit (CHC) has introduced the Shared Care Collective, an advisory board consisting of experts from various fields, both internal and external, to bolster sustainability efforts within the CHC business. This initiative aims to foster … Read the full press release

Dupixent Shows Remarkable Efficacy in Reducing COPD Exacerbations in Second Phase 3 Trial

(IN BRIEF) In a significant development, the second investigational Phase 3 trial of Dupixent® (dupilumab) for chronic obstructive pulmonary disease (COPD), known as NOTUS, has demonstrated promising results. The trial found that Dupixent reduced COPD exacerbations by 34% compared to … Read the full press release

Sanofi and Teva Collaborate on Inflammatory Bowel Disease Treatment, TEV’574, in $1.5 Billion Deal

(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release

Sanofi Collaborates with Janssen on Vaccine for Extraintestinal Pathogenic E. coli

(IN BRIEF) Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize a vaccine candidate for extraintestinal pathogenic E. coli (ExPEC) that is currently in Phase 3 of clinical trials. ExPEC … Read the full press release

Sanofi’s ALTUVIIIO Granted Marketing Authorization in Japan for Hemophilia A Treatment

(IN BRIEF) The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO, a novel factor VIII replacement therapy used to control bleeding in patients with hemophilia A. ALTUVIIIO, also known as efanesoctocog alfa, stands out … Read the full press release

Global Campaign ‘The Meningitis Flag’ Launched to Raise Meningitis Awareness Ahead of Paris 2024 Paralympic Games

(IN BRIEF) Meningitis Research Foundation, the Confederation of Meningitis Organisations (CoMO), and Sanofi have united to introduce ‘The Meningitis Flag,’ a worldwide campaign aimed at increasing awareness in the fight against meningitis. The campaign, supported by para-athletes including Ellie Challis, … Read the full press release

La exministra francesa de Igualdad de Género se une al consejo asesor DE&I de Sanofi

(NOTICIA EN BREVE) Sanofi ha nombrado a Elisabeth Moreno, exministra francesa de Igualdad de Género, Diversidad e Igualdad de Oportunidades, para su Junta de Diversidad, Equidad e Inclusión (DE&I) para los próximos tres años. El consejo asesor se creó en … Read the full press release

Former French Minister for Gender Equality joins Sanofi’s DE&I advisory council

(IN BRIEF) Sanofi has appointed Elisabeth Moreno, former French Minister for Gender Equality, Diversity and Equal Opportunities, to its Diversity, Equity and Inclusion (DE&I) Board for the next three years. The advisory council was created in 2022 to support Sanofi’s … Read the full press release

Patients as Partners Europe Returns to London and Announces Agenda Highlights

(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will take place in London on June 12-13, 2023. The event will focus on achieving greater representation in clinical research, building … Read the full press release

Sanofi gains full control of nirsevimab in US with new contractual agreements

(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab) in the United States. Under the new arrangements, Sanofi will have full commercial control of nirsevimab in the U.S. Sanofi … Read the full press release

Sanofi’s Acquisition of Provention Bio Expands Immune-Mediated Disease Portfolio

(IN BRIEF) Sanofi has agreed to acquire Provention Bio, a U.S.-based biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, for $2.9 billion. The acquisition includes Provention Bio’s first-in-class therapy for type 1 diabetes, TZIELD, which was approved in the … Read the full press release

Sanofi releases Q4 2022 Memorandum for investors to use in financial modeling

(PRESS RELEASE) PARIS, 4-Jan-2023 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that its Q4 2022 Memorandum for modelling purposes is now available on the “Investors” page of the company’s website. This … Read the full press release

Sanofi veröffentlicht das Q4 2022 Memorandum für Investoren zur Verwendung bei der Finanzmodellierung

(PRESSEMITTEILUNG) PARIS, 4-Jan-2023 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert, hat bekannt gegeben, dass sein Memorandum für das 4. Quartal 2022 zu Modellierungszwecken jetzt auf der Seite „Investoren“ der Website … Read the full press release

Sanofi und IGM Biosciences kooperieren bei einer neuen Klasse von Antikörper-Medikamenten zur Behandlung von Krebs, Immunologie und entzündlichen Erkrankungen

(PRESSEMITTEILUNG) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert , hat eine exklusive weltweite Kooperationsvereinbarung mit IGM Biosciences, Inc. (Nasdaq: IGMS), einem Biotechnologieunternehmen im klinischen Stadium, das sich auf … Read the full press release

Sanofi and IGM Biosciences and partner over new class of antibody medicines for the treatment of cancer, immunology, and inflammatory diseases

(PRESS RELEASE) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced an exclusive worldwide collaboration agreement signed with IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and … Read the full press release

Sanofi gibt auf seinem Immunology Investor Event ein Update zu seiner Immunologie-Strategie bekannt

(PRESSEMITTEILUNG) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert , hat angekündigt, dass das Unternehmen auf seinem Immunology Investor Event, das am Dienstag, den 29. März ab 14:00 Uhr … Read the full press release

Sanofi to provide an update on its Immunology strategy at its Immunology Investor Event

(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that the company will provide an update on its Immunology strategy at its Immunology Investor Event, which is taking place … Read the full press release

Sanofi adds first vaccine candidate against acne to its R&D pipeline with the take over of an Austrian privately held biotechnology firm

Origimm brings expertise in antigen discovery for immune modulation of skin microbiome-associated disorders Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide Sanofi to leverage its next-generation mRNA platform to unlock … Read the full press release

Sanofi to add Rezurock™ to its transplant portfolio with the acquisition of Kadmon Holdings, Inc.

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy (PRESS RELEASE) PARIS, 8-Sep-2021 — /EuropaWire/ — Sanofi … Read the full press release

Drugs for Neglected Diseases initiative: first all-oral treatment for Human African trypanosomiasis (sleeping sickness) gets US Food and Drug Administration (FDA) approval

(PRESS RELEASE) PARIS, 20-Jul-2021 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced fexinidazole approval by the US Food and Drug Administration (FDA) as the first all-oral treatment for both stages of the … Read the full press release

Sanofi launches more impactful Corporate Social Responsibility (CSR) strategy

Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines (PRESS RELEASE) PARIS, 7-Apr-2021 — … Read the full press release

Sanofi gains full global rights to a promising antibody for inflammatory disorders with the acquisition of Kymab

(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The agreement includes an upfront payment … Read the full press release

The COVID-19 vaccine based on Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant system secures 300 million doses order from the European Commission (EC)

Agreement signed today supports scale-up of manufacturing capabilities in several European countries Vaccine candidate uses Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system (PRESS RELEASE) PARIS, 18-Sep-2020 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused … Read the full press release

ESMO Virtual Congress 2020: Libtayo positive pivotal data offer hope for the treatment of advanced basal cell carcinoma, a difficult-to-treat cancer

Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial 31% objective response rate seen in trial patients, and an estimated 85% of responses … Read the full press release

Dr. Jean-Christophe Rufin to succeed Xavier Darcos as President of Sanofi Espoir Corporate Foundation

(PRESS RELEASE) PARIS, 18-Sep-2020 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced it has appointed Dr. Jean-Christophe Rufin as President of the Sanofi Espoir Corporate Foundation, aimed at reducing inequalities in health … Read the full press release

Sanofi tender offer for Principia Biopharma outstanding shares, August 28 – September 25, 2020

(PRESS RELEASE) PARIS, 28-Aug-2020 — /EuropaWire/ — French multinational pharmaceutical company Sanofi announces its intention to commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Principia Biopharma Inc. for $100 per share … Read the full press release

Immune-mediated diseases biopharmaceutical Principia Biopharma Inc. acquired by Sanofi for approximately EUR 3.1 billion ($3.68 billion)

Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central … Read the full press release

COVID-19: Sanofi increases production capacity of hydroxychloroquine; commits to donate 100 million doses

Sanofi to provide Plaquenil® (hydroxychloroquine) wherever possible, while securing appropriate supply levels for current approved indications; The company already increased its production capacity by 50% and is on track to further increase production over the coming months; Ongoing global clinical … Read the full press release

Sanofi announces second collaboration as it strives to develop a novel COVID-19 vaccine candidate

(PRESS RELEASE) PARIS and LEXINGTON, MA, U.S.A, 27-Mar-2020 — /EuropaWire/ — Sanofi Pasteur collaborates with Translate Bio (NASDAQ: TBIO) to develop a novel mRNA vaccine for COVID-19. Both companies will jointly investigate multiple candidates with the goal of advancing an … Read the full press release

Sanofi completes the divestment of its European generics business Zentiva to Advent

PARIS, 04-Oct-2018 — /EuropaWire/ — Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The transaction was finalized ahead of schedule for €1,9 billion (enterprise value). Sanofi announced the beginning … Read the full press release

Sanofi launches worldwide stock purchase plan reserved for its employees

A plan taking place in almost 80 countries Subscription per five shares entitle the employee to one matching share[1] PARIS, 12-Jun-2018 — /EuropaWire/ — Sanofi launches today “Action 2018”, a worldwide stock purchase plan reserved for its employees. In doing such a … Read the full press release

Dupixent demonstrated significant improvement in multiple asthma endpoints in two Phase 3 clinical trials

Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled asthma, irrespective of minimum baseline eosinophil levels or other biomarkers of Type 2 inflammation Greater … Read the full press release

John C. Reed, M.D. Ph.D. to succeed Elias Zerhouni, M.D. as Head of Global Research and Development at Sanofi

PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post … Read the full press release

Sanofi: the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for Sanofi’s acquisition of Bioverativ has expired

PARIS, 26-Feb-2018 — /EuropaWire/ — Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Bioverativ Inc. (“Bioverativ”, NASDAQ: BIVV) has expired. On February 7, … Read the full press release